Picture loading failed.

Pre-made Tadocizumab benchmark antibody (Fab, anti-ITGA2B;ITGB3 therapeutic antibody, Anti-BDPLT16/BDPLT2/CD41/CD41B/GP2B/GPIIb/GT/GT1/GTA/HPA3/PPP1R93;BDPLT16/BDPLT2/BDPLT24/CD61/GP3A/GPIIIa/GT/GT2 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tadocizumab is a humanized monoclonal antibody that acts on the cardiovascular system. It binds to integrin αIIbβ3, a fibrinogen and fibronectin receptor found on platelets.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-542-1mg 1mg 3090
GMP-Bios-ab-542-10mg 10mg Inquiry
GMP-Bios-ab-542-100mg 100mg Inquiry
GMP-Bios-ab-542-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Pre-Made Tadocizumab biosimilar, Fab, Anti-ITGA2B;ITGB3 Antibody: Anti-BDPLT16/BDPLT2/CD41/CD41B/GP2B/GPIIb/GT/GT1/GTA/HPA3/PPP1R93;BDPLT16/BDPLT2/BDPLT24/CD61/GP3A/GPIIIa/GT/GT2 therapeutic antibody
INN Name Tadocizumab
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2005
Year Recommended2006
CompaniesPDL BioPharma;Yamanouchi
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedCoronary artery restenosis;Stroke;Thrombosis
Development Techna